title: Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas.
abstract: Little is known about differences in the expression, localization, and function of the two dopamine D2 receptor subtypes, D2short and D2long (D2s and D2l), in either normal or adenomatous pituitary. We investigated the messenger RNA (mRNA) expression of the D2 receptor (D2R) subtypes in clinically nonfunctioning pituitary adenomas by in situ hybridization using subtype-specific oligonucleotides. The five normal pituitaries studied expressed similar ratios of D2R subtypes mRNA with a predominant expression of the D2l isoform. In 2 of 18 clinically inactive adenomas no D2R mRNA was found, whereas in 16 a heterogeneous expression of D2R isoforms was observed. Six adenomas expressed only the D2l and 2 adenomas only the D2s subtype mRNA; the remaining 8 expressed extremely varying proportions of the two subtypes. The D2R was found only in a subset of the nonfunctioning adenoma cells. In gonadotropin-immunopositive adenomas, the D2R was mainly localized in LH- and FSH-immunopositive cells. Probably because of the heterogeneous D2R subtype expression, suppression of cell proliferation was observed in only 3 of 9 adenoma cell cultures in which the growth inhibitory effect of bromocriptine was studied. Although there is some evidence that the presence of the D2s receptor subtype favors the growth inhibitory response to bromocriptine, further studies with a larger number of inactive adenomas are needed to confirm this speculation.
authors.affiliation: Max-Planck-Institute of Psychiatry, Clinical Institute, Department of Endocrinology, Munich, Germany. renner@mpipsykl.mpg.de
authors.forename: U
authors.initials: U
authors.lastname: Renner
authors.forename: T
authors.initials: T
authors.lastname: Arzberger
authors.forename: U
authors.initials: U
authors.lastname: Pagotto
authors.forename: S
authors.initials: S
authors.lastname: Leimgruber
authors.forename: E
authors.initials: E
authors.lastname: Uhl
authors.forename: A
authors.initials: A
authors.lastname: Müller
authors.forename: M
authors.initials: M
authors.lastname: Lange
authors.forename: A
authors.initials: A
authors.lastname: Weindl
authors.forename: G K
authors.initials: GK
authors.lastname: Stalla
mesh_terms: D000236:Adenoma / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001971:Bromocriptine / Q000627:therapeutic use; D016022:Case-Control Studies; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000166:cytology / Q000378:metabolism*; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis*; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D014407:Tumor Cells, Cultured
chemical_list: D018491:Dopamine Agonists; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2; D001971:Bromocriptine